Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral and baby care, women's health, wound care, and other essential health products; tampons; cosmetics; and vitamins and supplements. It sells its products under the Benadryl, Calpol, Motrin, Nicorette, Rhinocort, Tylenol, Zarbee's Naturals, and Zyrtec; Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Neutrogena, OGX, and Rogaine; BAND-AID, Carefree, Desitin, Johnson's, Listerine, o.b., and Stayfree; and ORSL, Clean & Clear, Versalie, Benylin, Daktarin, Imodium, Johnson's Baby, Johnson's Adult, Maui Moisture, Microlax, Motilium, Neosporin, Neostrata, Pepcid, Pulmicort, Regaine, Sudafed, and Visine/Vispring/Visclear brands. Kenvue Inc. was incorporated in 2022 and is headquartered in Summit, New Jersey.

Currency in USD	2025
Operating Income	2.41 Billion
Income Before Tax	2.00 Billion
Income Tax Expense	529.00 Million
Net Income	1.47 Billion
Eps	0.77
Epsdiluted	0.76
Weighted Average Shs Out	1.92 Billion
Weighted Average Shs Out Dil	1.92 Billion
Research And Development Expenses	382.00 Million
Selling General And Administrative Expenses	6.09 Billion
Depreciation And Amortization	557.00 Million
Interest Expense	430.00 Million
Interest Income	51.00 Million
Net Interest Income	-379 Million
Premiums Earned	N/A
Policyholder Benefits	N/A
Gross Profit	8.79 Billion
Ebitda	2.97 Billion
Source	edgar
Ebit	2.43 Billion

Kenvue Inc. Annual Reports (10-K)